Navigation Links
GVAX in Medical News

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

Cell Genesys, Inc. (Nasdaq: CEGE) today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with operable pancreatic cancer who received GVAX after su...

Experimental Cancer Vaccines Show Promise

...ented Tuesday at the American Association for Cancer Research annual meeting, in San Diego. A second study, out of the Netherlands, found that the gvax vaccine stimulated a significant immune response in men with prostate cancer. Five out of six participants receiving the highest dose of vaccine showe...

Immunotherapy: enlisting the immune system to fight cancer

...ic hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilumumab: ...phase I trial, they observed that a combination of gvax immunotherapy with ipilimumab lowered prostate-spe...s. Higher doses of ipilimumab combined with the gvax vaccine is showing a lot of success in increasing ...

Cell Genesys to Present at the Cowen and Company and the Lehman Brothers Healthcare Investor Conferences

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys Reports Fourth Quarter and Year-End 2007 Results

... potential association between immune responses to gvax immunotherapy for prostate cancer and increase...irst of two ongoing Phase 3 clinical trials of gvax immunotherapy for prostate cancer, completed a ... Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials ...

Combo Treatment Best for Melanoma, Advanced Ovarian Cancer

...ce a protein called GVAX. When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting a more energetic attack o...mune response spurred by the vaccine, researchers studied whether combining gvax vaccines with monoclonal antibody therapy could lengthen remissions and que...

Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer

... When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting ... researchers have begun studying whether combining gvax vaccines with monoclonal antibody therapy could le... patients who had previously been immunized with a gvax vaccine. The new study, a joint effort of Dana-...
GVAX in Medical Technology

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial i...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

Conference Call Scheduled for 10:00 a.m. ET Today SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of...

Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

...state Cancer Session) -- Oral presentation beginning at 11:30 a.m. local time on Monday, June 2, 2008. -- "Expanded phase 1 combination trial of gvax immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)" (Abstract #5146, Geni...

Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting

... hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimum...limumab in combination with the Cell Genesys, Inc. gvax immunotherapy for prostate cancer (an investig...nsion cohort (3 mg/kg ipilimumab). The dose of gvax immunotherapy for prostate cancer used in this...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

...ed follow-up data from a Phase 2 clinical trial of gvax immunotherapy for pancreatic cancer which was cond...ients with operable pancreatic cancer who received gvax after surgical resection of their tumor and adjuva...ent surgery and adjuvant therapy without receiving gvax indicated that the median overall survival of the ...
GVAX in Biological News

Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection

...eration and allows both Tregs and Teff cells to proliferate in response to exposure to self-antigen. Interestingly, combination of CLTA4 blockade with gvax selectively primes the anti-tumor Teff cells for action. This led to greater infiltration of Teff cells into the tumor, and eventually to tumor reject...
GVAX in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...n Bavituximab in Prostate Cancer II-54 Cell Genesys Reveals Data of gvax Immunotherapy for Treatment of Prostate Cancer II-54 Bioponic Phyto...to Take Over Rights of a New Marker Technology II-78 Cell Genesys's gvax Prostate Cancer-Treatment Attains FDA's Fast Track Tag II-78 Envisi...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

...pril 12-16, 2008 in San Diego: -- "Dendritic and T cell functions in patients with metastatic hormone- refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session) - Oral presentation scheduled for Monday, A...

Cell Genesys to Present at the BIO CEO and Investor Conference

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys to Webcast Third Quarter 2007 Conference Call

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys to Present at the BIO Investor Forum

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

...c cancer drug market to more than double by 2016. The new Pharmacor report entitled Pancreatic Cancer finds that Pharmexa's GV1001 and Cell Genesys's gvax will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan....

Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...
Other Tags
(Date:6/2/2015)... June 02, 2015 The Down Syndrome ... Potter from the hit show Glee as the keynote ... Walk in Pleasant Prairie, WI. The event aims to ... in Racine, Kenosha, and Walworth counties. ... join us for this important event," says Dawn Nuoffer, ...
(Date:6/2/2015)... York, NY (PRWEB) June 02, 2015 ... Profemur hip replacement lawsuit ( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) is ... County. According to court documents, opening statements were ... asserting that laser etchings on the Profemur hip ... fracture, causing it to snap just three years ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Tronics, a ... deploying its growth strategy to benefit from the significant ... Yole Développement’s May 2015 Status of the MEMS Industry ... sharply and reach $6.6B in 2020,” says Frederic Breussin, ... Développement . , The analyst adds that “although the ...
(Date:6/2/2015)... ANT Wireless, proven innovator in ultra-low power ... new products implementing the ANT+ Fitness Equipment Control (FE-C) ... in their bike trainer products, built to create an ... the FE-C device profile in its Vortex Smart and ... indoor training software, while Kinomap has added FE-C support ...
(Date:6/2/2015)... Acara Partners has seen a spike in demand for ... as is now required by recent Google search algorithm changes. ... several new clients in the medical aesthetics vertical, are anxious ... meet Google’s new requirements,” commented Fran Acunzo, CEO of Acara ... education, non-profits, and the business world.” , Back in ...
Breaking Medicine News(10 mins):Health News:Glee star Lauren Potter helps Down Syndrome Association of WI raise awareness, support 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 3Health News:Tronics Aims to Benefit from Major Growth of Sensors and Related Technologies for Healthcare Applications 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 3Health News:Acara Partners Expands Website and Digital Offerings 2
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... 2015  Through a well-rounded UAS delegation representing private industry, ... strong showing at AUVSI,s Unmanned 2015 conference last week in ... Ohio,s UAS industry met with over 200 hundred ... along the UAS ecosystem. "Our message is ... for Aerospace Rich Knoll . "If you want to ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
Other Contents